35
Endo Pharmaceuticals Holdings (ENDP)
When Endo got its pain-relieving patch Lidoderm approved by the U.S. Food & Drug Administration in 1999, the pharmaceutical company thought it would address a tiny market of 200,000 people who suffer pain related to shingles. But the product has been snapped up by everyone from weekend warriors with occasional back pain to office workers who have carpal tunnel syndrome. Clearly pain pays: In the quarter ended Mar. 31, Endo reported 48% sales growth and 50% earnings per share growth. The company expects sales of Lidoderm to skyrocket 26%, to at least $530 million. Endo is working on several other pain-relieving products, hoping to address a range of age and disease-related disorders, including cancer and neuropathic pain.
Company Info |
|
| 2005 Rank | NR |
| Market Value* ($ Millions) | 4,176.6 |
| Sales* ($ Millions) | 887.5 |
| Sales Growth (3-yr. avg. annual) |
24.5 % |
| Profits* ($ Millions) | 209.0 |
| Profit Growth (3-yr. avg. annual) | 89.0 % |
| Return on Inv. Capital (3-yr.) | 19.2 % |
| Share Price 12-Mo. Hi/Lo | 34/19 |
| Share Price As of 4/28/06 | 31 |
| Return on Equity | 22.9 % |
| P/E Ratio | 20 |
| No. of Employees | 710 |
| Industry | Pharmaceuticals |
| CURRENT MARKET INFO | ENDP > |
| COMPANY WEB SITE > | |
| Location | Chadds Ford, Pa. |
| Phone | 610 558-9800 |
*Trailing 12 months
Stock price data as of 4/28/06
DATA: Standard & Poor's Compustat
Related Articles
Endo: The Pain and the Gain
No Pain, Some Gain
Hey, You Don't Look So Good
There's Entrancing News About Hypnosis
Company Snapshot
Endo Pharmaceuticals Holdings engages in the research, development, sale, and marketing of prescription pharmaceuticals to treat and manage pain. Its products include Lidoderm for the relief of the pain associated with post-herpetic neuralgia; Percocet, Percodan, and OxyContin to treat moderate-to-moderately severe pain; Frova to prevent menstrual migraine; Synera, a topical local anesthetic patch to provide local dermal anesthesia in children and adults. The company's generic pharmaceuticals comprise Endocet, a generic oxycodone hydrochloride and acetaminophen product; and morphine sulfate extended-release tablets for pain management. Its pipeline portfolio includes Oxymorphone ER and IR tablets to treat acute post-operative pain; Frova MM in Phase III clinical trial development to treat menstrual migraine; Rapinyl tablet in Phase III clinical trial development to treat breakthrough cancer pain; Chronogesic in Phase II development to treat patients with opioid responsive chronic pain; and Transdermal Sufentanil Patch in early-stage clinical development to provide relief of moderate-to-severe chronic pain. The company's pipeline portfolio also includes Topical Ketoprofen Patch in Phase II clinical trials to treat acute pain associated with soft-tissue injuries; LidoPAIN BP in Phase II clinical trial development to treat acute lower back pain; and Propofol IDD-D that is at the end of Phase II clinical trial development to maintain anesthesia in adults during surgery and for sedation of adults hospitalized in an intensive-care setting. It serves physicians in pain management, neurology, surgery, anesthesiology, oncology, and primary care, as well as serves retail pharmacies and other health-care professionals through wholesale drug distributors in the U.S. The company has strategic alliances with SkyePharma and Penwest Pharmaceuticals. Endo Pharmaceuticals Holdings was incorporated in 1997 and has its headquarters in Chadds Ford, Pa.
Data provided by 
